Data as of Nov 26
| +0.16 / +1.20%|
The 6 analysts offering 12-month price forecasts for Aratana Therapeutics Inc have a median target of 24.00, with a high estimate of 38.00 and a low estimate of 18.00. The median estimate represents a +77.78% increase from the last price of 13.50.
The current consensus among 7 polled investment analysts is to Buy stock in Aratana Therapeutics Inc. This rating has held steady since November, when it was unchanged from a Move your mouse over past
months for detail
Move your mouse over a quarter or year to see how estimates have changed over time.